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Background: Evidence suggests CaHMBmay impact musclemass and/or strength in older adults, yet no long-term
studies have compared its effectiveness in sedentary and resistance training conditions. The purpose of this study
was to evaluate the effects of 24 weeks of CaHMB supplementation and resistance training (3 d wk−1) or CaHMB
supplementation only in ≥65 yr old adults.
Methods: This double-blinded, placebo-controlled, trial occurred in twophasesunder ad libitum conditions. Phase I
consisted of two non-exercise groups: (a) placebo and (b) 3 g CaHMB consumed twice daily. Phase II consisted of
two resistance exercise groups: (a) placebo and resistance exercise and (b) 3 g CaHMB consumed twice daily and
resistance exercise (RE). Strength and functionalitywere assessed in both phaseswith isokinetic leg extension and
ﬂexion at 60°·s−1 and 180°·s−1 (LE60, LF60, LE180, LF180), hand grip strength (HG) and get-up-and-go (GUG).
Dual X-Ray Absorptiometry (DXA) was used to measure arm, leg, and total body lean mass (LM) as well as total
fat mass (FM). Muscle Quality was measured for arm (MQHG = HG/arm LM) and Leg (MQ60 = LE60/leg LM)
(MQ180 = LE180/leg LM).
Results: At 24 weeks of Phase I, change in LE60 (+8.8%) and MQ180 (+20.8%) for CaHMB was signiﬁcantly
(p b 0.05) greater than that for placebo group. Additionally, only CaHMB showed signiﬁcant (p b 0.05) improve-
ments in total LM (2.2%), leg LM (2.1%), and LE180 (+17.3%), though no treatment effect was observed. Phase II
demonstrated that RE signiﬁcantly improved total LM (4.3%), LE60 (22.8%), LE180 (21.4%), HG (9.8%), and GUG
(10.2%) with no difference between treatment groups. At week 24, only CaHMB group signiﬁcantly improved
FM (−3.8%) and MQHG (7.3%); however there was no treatment main effect for these variables.
Conclusion: CaHMB improved strength and MQ without RE. Further, RE is an effective intervention for improving
all measures of body composition and functionality.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
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ulations and must be addressed through preventive intervention
(Marcell, 2003).
Research has suggested that nutrition and/or physical activity may
attenuate age-associated muscle loss by directly inﬂuencing myogenic
processes and protein turnover (Evans, 1995). Nutrition and exercise
strategies to increasemuscle mass in elderly individuals include intakes
of protein (1.2–1.6 g/kg bodyweight daily) above the current recom-
mended dietary allowance (RDA) levels (Campbell et al., 1994), and
resistance training (Bamman et al., 1998). Speciﬁcally, leucine has
been reported to be the crucial amino acid within protein to combat
loss of muscle and/or strength (Katsanos et al., 2005, 2006). One of
the primary mechanisms by which leucine prevents muscle wasting is
by its conversion to β-hydroxy-β-methylbutyrate (HMB) (Wilson
et al., 2008). HMB has been suggested to mitigate muscle loss with
aging, disease, or exercise stress by attenuating protein degradation
(Eley et al., 2007; Wilkinson et al., 2013), and up-regulating protein
synthesis (Wilkinson et al., 2013). Evidence of HMB's role in building
muscle comes from human intervention trials among mostly young,
exercising adults; although an emerging number of studies are available
with HMB in the elderly withmixed results. Flakoll et al. (2004) report-
ed that supplementing the diets of older (~76.7 yrs), sedentary women
with 2 g CaHMB in combinationwith 5 g arginine, and 1.5 g lysine daily
for 12 weeks signiﬁcantly improved their functionality and fat free
mass, while a year-long supplementation period in both men and
women has been demonstrated to improve in lean mass but not
strength or functionality (Baier et al., 2009). Vukovich et al. (2001)
data suggested that 3 g HMB can have a positive effect on body compo-
sition and strength measures in older adults (70 ± 1 yr) that are
initiating a moderate exercise program. In their study, the participants
consumed 3 g of CaHMB per day and demonstrated a signiﬁcant
decrease in % fat but a non-signiﬁcant increase in FFM using skinfold
analysis when compared to the placebo group (Vukovich et al., 2001).
In addition, they reported improvements in one-repetition maximum
for the upper body pull-down exercise in the HMB group that was sig-
niﬁcantly greater than changes seen in the placebo group. However,
no signiﬁcant improvements were observed for lower body strength.
It is unknown whether a longer period of HMB supplementation and
training may have resulted in greater changes in FFM and strength.
Clearly, additional studies are needed to understand the role of HMB
alone, with and without resistance training, on muscle, strength and
functionality in older men and women.
A potential, but unexplored beneﬁt of HMB is its effect on fat tissue.
Recently, Wilson et al. (2012) found that HMB lowered body fat from
old to very old age in rats. Studies evaluating elderly individuals have
demonstrated that strength training improves muscle quality (MQ)
(Tracy et al., 1999) and decreases intramuscular fat (Newman et al.,
2003). Muscle quality is a measure of strength relative to muscle mass
and is considered a predictor of health status, mortality and a better
indicator of muscle function than strength alone (Tracy et al., 1999). In
theory, if HMB decreases fat while at the same time increasing muscle
mass, then this may be reﬂected in an increase in MQ measurements.
There is a need, however, to examine the potential beneﬁt of HMB
with and without resistance training, in older human populations.
Therefore the purpose of this study was to evaluate the effects of 12
and 24 weeks of HMB supplementation on muscle mass, fat mass, MQ,
strength, and function with and without a progressive resistance train-
ing program in healthy older men and women following an adequate
protein diet.
2. Methods
2.1. Participants
Participants were screened for the following inclusion criteria: male
or female ≥65 years; Geriatric Nutritional Risk Index ≥ 92 (21);BMI N 20.0 kg m−2, but b30.0 kg m−2 and ambulatory (Bouillanne
et al., 2005). The exclusion criteria were major surgery within four
weeks of enrollment; active malignant disease; immunodeﬁciency
disorder; history of diabetes; partial or full artiﬁcial limb; signiﬁcant
cardiovascular, metabolic or endocrine disease; antibiotic use within
one week of enrollment; history of allergies to product ingredients;
major disease of the gastrointestinal tract, signiﬁcant neurological
or psychological disorder; actively pursuing weight loss; and cur-
rently taking an excluded concomitant treatment including weight
loss or gain aids (e.g., steroids, meal replacements, protein and/or
amino acids).
2.2. Study design
This randomized, double-blinded, placebo-controlled, mixed facto-
rial clinical trial was conducted in two phases (Fig. 1): Phase I consisted
of two non-exercise (NE) groups: (a) ad libitum diet plus placebo
(NEPLA) and (b) ad libitum diet plus CaHMB (NEHMB). Phase II consisted
of two resistance exercise (RE) groups: (a) ad libitum diet plus placebo
and resistance exercise (REPLA) and (b) ad libitum diet plus CaHMB and
resistance exercise (REHMB). After recruitment and enrollment for Phase
I was completed, recruitment and enrollment for Phase II was
initiated. No subject was allowed to participate in both Phase I and
Phase II. Phase II included all the same outcome measures in Phase I,
with the addition of speciﬁc resistance exercise outcome measures
(i.e., 5RM strength for the bench press, leg press, and leg extension
exercises). Study volunteers signed informed consent forms that were
approved by the university's institutional review board.
After eligibility was determined, participants were randomly
assigned to treatment groups by a computer-generated, pseudo-
random permuted block algorithm for Phases I and II. The randomiza-
tion was further stratiﬁed by sex to balance randomization for each
gender. Upon enrollment participants were sequentially assigned a
subject number and given a corresponding randomization stratum. In
a double-blind fashion, participants were given a placebo (PLA,
200 mg calcium + 4 g carbohydrate as packets of powder) or calcium
beta-hydroxy-beta-methylbutyrate (HMB, 1.5 g CaHMB + 4 g carbo-
hydrate as packets of powder). Instructions were given to mix their
assigned study product in a non-carbonated, non-alcoholic beverage
of their choice (e.g., milk, water, juice) and drink ad libitum. Two
packets were mixed and consumed every day during the study
period.
The study evaluation period for each participant in Phases I and II
was 24 weeks. Testing was performed at week 0 (pre-test), 12 weeks
(mid-test), and 24 weeks (post-test), and consisted of body composi-
tion, muscle strength, functional movement, three-day dietary recall,
blood markers, and urinalysis for HMB consumption. All testing took
place on the same day such that blood draws, urinalysis, and body com-
position were tested in the morning after a 12-hour fast. All tests were
performed in a metabolic and body composition laboratory at the
university.
2.3. Compliance
Product intake was recorded on individual intake logs, which were
returned to the laboratory and monitored. Urinary HMB levels were
used as markers to indicate test treatment compliance. The ﬁrst morning
urine void was collected at pre-, mid-, and post-testing using a ‘clean
catch’ method previously described (Nissen et al., 1996). Urine samples
(100 μl) were placed in 2 mL tubes, frozen at −70° C, and sent on dry
ice to Metabolic Technologies (Ames, IA) for analysis. HMB levels
increased from pre- to mid-testing (1010 ± 1408 nmol ml−1) and
from pre- to post-testing (972 ± 1182 nmol ml−1) for the NEHMB and
REHMB groups compared to minimal changes of 11.7 ± 25.7 nmol ml−1
and 25.5 ± 43.3 nmol ml−1, respectively, for the NEPLA and REPLA
groups.
Fig. 1. Subject randomization and evaluability ﬂowchart for non-exercising group (A) and exercising group (B).
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Fasting blood samples were drawn from the antecubital vein at pre-
and post-testing only. Sampleswere sent to a commercial laboratory for
analysis (Quest Diagnostics, Norman, OK). Markers analyzed included
total protein, albumin, prealbumin, hemoglobin, hematocrit, red blood
cells (RBC), white blood cells (WBC), differentials (percent and absolute
values for lymphocytes, monocytes, neutrophils, eosinophils, and baso-
phils), platelet count, glucose, blood urea nitrogen (BUN), creatinine,
sodium, potassium, chloride, calcium, magnesium, phosphorus, uric
acid, total cholesterol, triglycerides, serum glutamic oxaloacetic trans-
aminase (SGOT), serum glutamic pyruvic transaminase (SGPT), lactate
dehydrogenase (LDH), and total bilirubin.
2.5. Dietary assessment
Participants completed a three-day dietary recall at pre-, mid-, and
post-testing. Instructions for participants were to write down every-
thing consumed during two weekdays and one weekend day. These
data were entered into a software program (Food Processor, Version
8.6.0, ESHA Research, Salem, Oregon) that provided calculations of ab-
solute daily protein intake (g), relative daily protein intake (g kg−1),
and daily caloric intake (kcal). Average values for protein and caloric in-
take across each three-day period were recorded.
2.6. Body composition
Whole-body scans were performed at pre-, mid-, and post-testing
following a 12-hour fast using a dual-energy X-ray absorptiometry
(DXA) scanner (Lunar Prodigy Advanced, Madison, WI, Software ver-
sion 10.50.086). Images were analyzed with manufacturer-provided
software (LUNAR Radiation body composition program). Total fatmass (FM), total lean mass (LM), regional leg lean mass (left and
right), and regional arm lean mass (left and right) were measured.
Previously determined intraclass correlation coefﬁcients (ICC) and stan-
dard errors of measurement (SEM) for test–retest reliability using the
DXA scanner in this laboratory to measure 11 men and women
24–48 hours apart for total FM, LM, regional leg LM, and regional arm
LM were 0.97 and 0.93 kg, 0.99 and 0.61 kg, 0.99 and 0.03 kg, 0.99
and 0.02 kg, respectively.
2.7. Strength and function assessment
2.7.1. Handgrip strength
Handgrip (HG) strength was measured on the participant's domi-
nant hand (hand used to write with) using a standard hand-held dyna-
mometer (DHS-176, Detecto, Webb City, MO). The dynamometer
handle was adjusted so that the middle phalange of the third digit
was comfortably perpendicular to the long axis of the handle. In an
upright standing position, arms adducted, dominant forearm ﬂexed to
90°, and the wrist in a neutral position, participants were asked to
squeeze the dynamometer handle as forcefully as possible for 3 to 5 s.
Three trials were performed with about 30 second rest between trials.
Strong verbal encouragement was provided for each trial. Force output
in kg was recorded for each trial, and the average of the three trials was
analyzed as the representative HG strength value.
2.7.2. Isokinetic leg strength
Peak torque (PT) duringmaximal voluntary concentric isokinetic leg
extension and ﬂexion muscle actions was measured at pre-, mid-, and
post-testing using a calibrated isokinetic dynamometer (LIDO Multi-
Joint II, Loredan Biomedical,West Sacramento, CA) at randomly ordered
angular velocities of 60°·s−1 and 180°·s−1. All isokinetic testing was
performed on the dominant leg (assessed by kicking preference) unless
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leg, in which case the non-dominant legwas used for all testing. The leg
used at pre-testing was reassessed at mid- and post-testing. The center
of the rotation of the knee joint was visually aligned with the
dynamometer's axis of rotation, and restraining straps were positioned
over the hips and dominant thigh to prevent extraneous movements.
The lever arm was strapped to the distal leg just proximal to the
malleoli. At each angular velocity, participants performed four
movement-speciﬁc warm-up (practice) repetitions, which consisted
of leg extension and ﬂexion muscle actions at 25%, 50%, 75%, and
100% of their maximal perceived effort. Immediately following the
warm-up repetitions, each participant performed three maximal
leg extension and leg ﬂexion muscle actions in a ‘push-pull’ fashion
as hard and fast as they could for a total of six muscle actions
(three extensions and three ﬂexions). Three minutes of rest was
allowed between velocities. The average PT across the three repeti-
tions was used for analysis.
2.7.3. Bench press, leg press, and leg extension strength
Dynamic constant external resistance (DCER) strength testing was
performed only for Phase II (REPLA and REHMB groups) at pre-, mid-,
and post-testing. Participants completed a ﬁve repetition maximum
(5RM) test for the following exercises in order: bilateral leg extension,
bench press, and bilateral leg press. Prior to the 5RM testing, a
ﬁve-minute warm-up was completed on a stationary cycle ergometer
(Monark 828E, Vansbro, Sweden) at a self-selected intensity. Partici-
pants then completed two warm-up sets of 10 repetitions at 55% and
65% of their perceived maximum load. A maximum of ﬁve 5RM
attemptswere allowedwith three toﬁveminute rest between attempts.
Each successive load was increased by 2–4 kg for the bench press or
4–8 kg for the leg extension and leg press.When the subjectwas unable
to complete ﬁve repetitions during an attempt, the load (kg) from the
previous attemptwas recorded as the 5RM.When the subject completed
ﬁve repetitions during ﬁve successive attempts despite load increases, the
ﬁnal load (kg) used was recorded as the 5RM.
2.7.4. Get-up-and-go test
The get-up-and-go (GUG) test, which has been previously described
elsewhere (Podsiadlo and Richardson, 1991), was performed at pre-,
mid-, and post-testing as ameasure of functionality. GUGwasmeasured
as the time it took for a participant seated in a chair to stand up (without
assistance from their hands), walk forward briskly along a straight line
on the ﬂoor measured out to 3 m, turn around 180°, walk back toward
the chair briskly along the same three-meter line, turn around 180°
again, and sit back down in the chair (without assistance from their
hands). A standard digital stopwatch, press-backwooden chair without
padding, and red tape to mark the three-meter course on a level, tiled
concrete surfacewere used for the GUG test. The stopwatchwas started
upon the initiation of movement by the subject to stand up, stopped
when the subject was seated again, and recorded to the nearest 0.01 s.
Three attempts were performed, and the average of the three was
used as the representative GUG score.
2.7.5. Muscle quality
Muscle quality (MQ) was calculated as muscle strength relative to
muscle mass. MQ has been used and described previously as an indica-
tor of muscle function (Lynch et al., 1999; Tracy et al., 1999). MQ was
calculated for three separate tests: HG (kg) ÷ arm lean mass (kg) =
MQHG (kg kg−1); leg extension PT (Nm) at 60°·s−1 ÷ leg lean mass
(kg) = MQ60 (Nm kg−1); and leg extension PT (Nm) at 180°·s−1 ÷ leg
lean mass (kg) = MQ180 (Nm kg−1).
2.8. Resistance exercise
For Phase II, the progressive resistance exercise (RE) program
consisted of three sessions per week for 21 weeks (excluding threeweeks of testing). The volume of RE (number of sets per exercise per
week) was as follows: week 1 was pre-testing only, weeks 2 and 3 in-
cluded one set per exercise, week 4 was two sets, weeks 5–10 were
three sets, week 11 was one or two sets, week 12 was mid-testing
only, weeks 13 and 14 were one set, week 15 was two sets, weeks
16–22 were three sets, week 23 was one or two sets, and week 24
was post-testing only. All RE sessions were completed in the laboratory
using the same equipment used for testing and were supervised by
certiﬁed personal trainers. During each training session, participants
completed one to three sets of 8–12 repetitions for each exercise. Exer-
cises included the bench press, lat pulldown, bilateral leg press, hack
squat, and bilateral leg extension. For the bench press, bilateral leg
press, and bilateral leg extension exercises, 80% of the one repetition
maximum (1RM) determined at pre-testing was used as the load and
was progressively increased throughout the study. For the lat pulldown
and hack squat exercises, a self-selected load was used to achieve 8–12
repetitions. Each exercise set was separated by 2–5 min of rest. The
loads were progressively increased by 2–4 kg for the bench press, lat
pulldown, and leg extension or 4–8 kg for the leg press and hack
squat when participants were comfortably able to complete 12 repeti-
tions during the last two sets of any exercise for two consecutive
sessions.
2.9. Statistical analyses
As this was a pilot study, a relatively small sample size (n of approx-
imately 20 evaluable subjects for each treatment group/exercise group
combination) was chosen in order to gather data that may be used in
the design of future studies. Because of the exploratory nature of this
study, the primary analysis was the evaluable analysis: a participant's
outcome data were classiﬁed as evaluable until one or more of the
following events occurred: participant took an excluded concomitant
treatment (e.g., steroids, anabolic agents, amino acid/protein supple-
ments); assigned to the control group, but exhibited a urinary HMB
N0.5 μmol ml−1 atmid- or post-testing; did not have body composition
measurement pre- or post-testing; reported an average total protein
intake b0.8 g kg−1 body mass; consumed b67% of study product; and
in the REPLA and REHMB groups completed b60% of RE sessions.
Values are reported as mean raw change scores and the correspond-
ing standard errors. Analysis of variance (ANOVA) and/or paired t-tests
were used to analyze the change from baseline to 12 weeks and base-
line to 24 weeks for body composition, muscle strength, functionality,
muscle quality, dietary intake, blood markers, and HMB urinalysis
data. If the residuals from ANOVA did not follow a normal distribution
(not attributable to outliers), a Wilcoxon rank-sum test was used to
compare groups. The factors used in the model were: treatment × sex,
treatment, and sex. If there was a signiﬁcant interaction (p b 0.10),
then treatment differences were investigated separately for each sex
using the Stepdown Bonferroni (Holm) procedure. Adjusted p-values
from this procedure are presented in the footnotes of the tables for sig-
niﬁcant (p b 0.05) treatment effect values for sex. Adverse events and
serious adverse events were analyzed by appropriate categorical
techniques.
SAS® version 9.1.3 and 9.2 (SAS, Inc., Cary, NC)were used for all sta-
tistical analyses. All main effects were testedwith two-sided, 0.05 alpha
level tests, while interaction effects were assessed with two-sided, 0.10
alpha level tests.
3. Results
3.1. Phase I—no resistance exercise
During the course of the 24-week study, 43 subjects completed
Phase I and were considered protocol evaluable [n = 21 in NEPLA,
n = 22 in NEHMB]. Table 1 contains the demographic and baseline
characteristics.
Table 1
Characteristics of study participants.
Study Phase I Study Phase II
NEPLA NEHMB REPLA REHMB
Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM
Males/females 14/11 13/12 11/13 11/13
Age, yrs 72 ± 1 73 ± 1 73 ± 1 73 ± 1
Weight, kg 76 ± 4 73 ± 2 68 ± 3 74 ± 3
BMI kg m−2 25 ± 1 26 ± 05 25 ± 1 26 ± 1
Protein intake,
g/kg bwt
1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.2 ± 0.1
Body composition
Total lean mass, kg 24 ± 2 22 ± 1 21 ± 1 23 ± 1
Leg lean mass, kg 16 ± 1 14 ± 1 14 ± 1 15 ± 1
Total fat mass, kg 25 ± 2 24 ± 1 22 ± 1 24 ± 1
Isokinetic peak
torque (Nm)
Extensor 60°·s−1
Flexor 60°·s−1
97 ± 9
56 ± 5
80 ± 8
49 ± 4
75 ± 8
40 ± 3
84 ± 9
46 ± 4
Extensor 180°·s−1
Flexor 180°·s−1
61 ± 5
42 ± 4
49 ± 5
35 ± 2
51 ± 6
32 ± 2
56 ± 6
34 ± 2
Hand grip
strength, kg
31 ± 3 32 ± 2 26 ± 3 29 ± 2
Muscle quality (MQ)
MQ 60° s Nm kg−1 5.9 ± 0.3 5.4 ± 0.4 5.2 ± 0.4 5.3 ± 0.3
MQ 180° s Nm kg−1 3.8 ± 0.2 3.2 ± 0.2 3.5 ± 0.3 3.5 ± 0.2
MQ hand grip 5.8 ± 0.2 6.4 ± 0.2 5.4 ± 0.2 5.5 ± 0.2
Get up and go, s 5.2 ± 0.2 5.4 ± 0.4 5.6 ± 0.3 6.0 ± 0.6
Activities of
daily living
6.3 ± 0.3 6.4 ± 0.3 6.5 ± 0.3 6.6 ± 0.3
Table 2
Body composition (kg) and isokinetic strength (Nm) and changes after 12 week (mid-
test) and 24 week (post-test) supplementation with Placebo (PLA) or HMB in non-
exercising (NE) study subjects.
NEPLA NEHMB Treatment
main
effectsa
Mean ± SEM Within
group p
value
Mean ± SEM Within
group p
value
Weight, kg
Mid-test 0.2 ± 0. 3 – 0.8 ± 0.2 b0.01 –
Post-test −0.3 ± 0. 5 – 0.8 ± 0.3 0.02 –
Total lean mass, kg
Mid-test 0.2 ± 0.1 – 0.4 ± 0.1 b0.01 –
Post-test 0.2 ± 0.1 – 0.5 ± 0.1 b0.01 –
Leg lean mass, kg
Mid-test 0.1 ± 0.1 – 0.3 ± 0.1 0.01 –
Post-test 0.1 ± 0.1 – 0.3 ± 0.1 b0.01 ns (0.09)
Arm lean mass, kg
Mid-test 0.04 ± 0.03 – 0.05 ± 0.03 ns(0.06) –
Post-test 0.11 ± 0.04 0.02 0.07 ± 0.03 0.03 –
Total fat mass, kg
Mid-test 0.2 ± 0.3 – 0.3 ± 0.2 – –
Post-test 0.3 ± 0.4 – 0.6 ± 0.3 0.03 ns (0.06)
Isokinetic peak
torque (Nm)
Extensor, 60°·s−1
Mid-test 2.7 ± 2.2 – 4.8 ± 3.2 – –
Post-test −1.2 ± 2.1 – 7.7 ± 3.5 0.04 0.04
Flexor, 60°·s−1
Mid-test 1.7 ± 3.3 −6.3 ± 2.6 0.03 ns (0.08)
Post-test 0.5 ± 2.5 1.4 ± 1.5 – –
Extensor, 180°·s−1
Mid-test 5.0 ± 3.1 – 7.2 ± 1.7 b0.01 *1
Post-test 2.9 ± 3.2 – 8.5 ± 1.9 b0.01 –
Flexor, 180°·s−1
Mid-test 2.7 ± 3.0 – 2.9 ± 2.0 – –
Post-test 5.9 ± 2.8 ns
(0.052)
7.3 ± 3.6 ns
(0.052)
–
Grip strength, kg
Mid-test −0.3 ± 0.8 – −0.3 ± 1.1 – –
Post-test 0.6 ± 0.8 – 0.02 ± 0.9 – –
GUG, s
Mid-test −0.3 ± 0.2 – −0.2 ± 0.1 0.04 –
Post-test −0.6 ± 0.2 b0.01 −0.5 ± 0.1 b0.01 –
* indicates signiﬁcant treatment group by gender interaction (treatment p-value indicated
below for gender).
a p values reported for signiﬁcant main effects unless there was a signiﬁcant treatment
by gender interaction, in which case results are indicated in footnote.
1 Females: ns (0.07).
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With the exception of an increase in arm lean mass at post-testing,
no signiﬁcant changes in mass or body composition were observed in
the NEPLA group (Table 2). However, the NEHMB group experienced sig-
niﬁcant increases in total weight, total LM and leg LM at both mid- and
post- testing compared to baseline pre-testing (Table 2). Both arm lean
mass and total FM also had signiﬁcant increased at post- but not mid-
test (Table 2). No signiﬁcant differenceswere observed between groups.
3.1.2. Strength and functionality
Leg extensor PT did not change for either 60°·s−1 or 180°·s−1
throughout the study within the NEPLA group (Table 2). For the NEHMB
group, leg extensor PT 60°·s−1 signiﬁcantly increased at post-testing,
and for 180°·s−1 increased at both mid- and post-testing. Differences
between groups (NEPLA vs NEHMB) were signiﬁcant at post-testing
for 60°·s−1. Isokinetic leg ﬂexor PT did not change at mid- or post-
testing except for the following: leg ﬂexor PT transiently decreased for
60°·s−1 at mid-testing in the NEHMB group but was not different from
baseline at post-testing; there was a non-signiﬁcant (p = 0.052) in-
crease for 180°·s−1 at post-test in both treatment groups.
Handgrip strength did not change from baseline for either the NEPLA
or NEHMB groups (Table 2). Get-up-and-go time improved in the NEHMB
group at mid-testing (−0.2 ± 0.1 s, p = 0.04) and in both groups at
post-testing (−0.6 ± 0.2 s, p b 0.01, −0.5 ± 0.1 s, p b 0.01, NEPLA
and NEHMB, respectively), with no differences between groups.
3.1.3. Muscle quality
MQ60 was unaffected at mid- and post-testing for the NEPLA and
NEHMB groups, respectively (Table 3). MQ180 remained unchanged at
mid- and post-testing for the NEPLA group, but increased at mid- and
post- for the NEHMB group (Table 3). MQHG did not change at mid- or
post-testing for either the NEPLA or NEHMB group, respectively.
3.2. Phase II—resistance exercise
During the course of the 24-week study, 36 subjects completed
Phase II and were considered protocol evaluable [n = 20 in REPLA,n = 16 in REHMB]. Table 1 contains the demographic and baseline char-
acteristics for these participants.
3.2.1. Body weight and composition
There were no signiﬁcant changes in total body weight at mid- or
post-testing for either the REPLA or REHMB groups, respectively; however,
weight losswas signiﬁcantly greater in REHMBmales vs. REPLA atmid-test
(Table 4). Total, leg, and arm lean mass increased in both groups with
signiﬁcant (p b 0.05) differences (REPLA N REHMB) for men in total and
arm lean mass at both mid- and post-testing. Fat decreased in both
groups atmid- and only in REHMB at post-testing (Table 4)with no differ-
ences between groups.
3.2.2. Strength and functional movement
Bench press, leg press, and leg extensor 5RM signiﬁcantly increased
at mid- and post-testing for both the REPLA and REHMB groups (Table 4)
with no differences between groups. Isokinetic leg extensor PT at both
60°·s−1 and 180°·s−1 increased atmid- and post-testingwith nodiffer-
ences between groups. Isokinetic leg ﬂexor PT 60°·s−1 tended to in-
crease at mid- but not post-testing, while leg ﬂexor PT 180°·s−1
increased at post-testing in the REPLA group and at mid-testing in the
REHMB group (p = 0.052), with no differences between groups. Hand-
grip strength increased from baseline at both mid- and post-test for
Table 3
Muscle quality changes after 12 week (mid-test) and 24 week (post-test)
supplementation with Placebo (PLA) or HMB in non-exercising (NE) study subjects.
NEPLA NEHMB Treatment
main
effectsa
Mean ± SEM Within
group
Mean ± SEM Within
group
MQ 60°·s−1 Nm/kg
Mid-test 0.1 ± 0.2 – 0.2 ± 0.2 – –
Post-test −0.1 ± 0.1 – 0.3 ± 0.2 – –
MQ 180°·s−1 Nm/kg
Mid-test 0.2 ± 0.2 – 0.5 ± 0.1 b0.01 *1
Post-test 0.1 ± 0.2 – 0.5 ± 0.1 b0.01 0.049
MQ HG
Mid-test −0.1 ± 0.2 – −0.3 ± 0.3 – –
Post-test 0.02 ± 0.1 – −0.2 ± 0.2 – –
* indicates signiﬁcant treatment group by gender interaction (treatment p-value indicated
below for gender).
a p values reported for signiﬁcant main effects unless there was a signiﬁcant treatment
by gender interaction, in which case results are indicated in footnote.
1 Females: 0.01.
Table 4
Body composition (kg) and isokinetic strength (Nm) and changes after 12 week (mid-test)
and 24 week (post-test) supplementation with placebo (PLA) or HMB in resistance-
exercising (RE) study subjects.
REPLA REHMB Treatment
main
effectsa
Mean ± SEM Within
group p
value
Mean ± SEM Within
group p
value
Weight, kg
Mid-test 0.3 ± 0.2 ns(0.08) −0.6 ± 0.4 – *1
Post-test 0.4 ± 0.3 – −0.5 ± 0.6 – ns (0.06)
Total lean mass, kg
Mid-test 0.7 ± 0.1 b0.01 0.4 ± 0.2 0.03 *2
Post-test 0.9 ± 0.1 b0.01 0.7 ± 0.2 0.01 *3
Leg lean mass, kg
Mid-test 0.4 ± 0.1 b0.01 0.2 ± 0.1 ns
(0.08)
*4
Post-test 0.6 ± 0.1 b0.01 0.5 ± 0.2 0.01 –
Arm lean mass, kg
Mid-test 0.21 ± 0.03 b0.01 0.11 ± 0.04 0.01 *5
Post-test 0.24 ± 0.04 b0.01 0.13 ± 0.06 ns
(0.053)
*6
Total fat mass, kg
Mid-test −0.4 ± 0.2 0.02 −0.9 ± 0.3 0.01 –
Post-test −0.5 ± 0.3 ns
(0.096)
−0.9 ± 0.4 0.04 –
Bench press, 5RM
Mid-test 16 ± 2 b0.01 19 ± 1 b0.01 *7
Post-test 31 ± 3 b0.01 32 ± 2 b0.01 –
Leg press, 5RM
Mid-test 118 ± 14 b0.01 131 ± 18 b0.01 –
Post-test 259 ± 23 b0.01 275 ± 32 b0.01 –
Leg extensor, 5RM
Mid-test 36 ± 4 b0.01 37 ± 4 b0.01 –
Post-test 78 ± 6 b0.01 74 ± 6 b0.01 –
60°·s−1 extensor
peak torque, Nm
Mid-test 10.8 ± 3.1 b0.01 5.3 ± 2 0.03 –
Post-test 17.1 ± 3.8 b0.01 9.1 ± 2 b0.01 ns(0.09)
180°·s−1 extensor
peak torque, Nm
Mid-test 5.0 ± ±2 0.01 3.4 ± 2.0 – –
Post-test 11.0 ± 3 b0.01 5.7 ± 2.5 0.04 –ns(0.09)
60°·s−1 ﬂexor peak
torque, Nm
Mid-test 4.7 ± 1.3 b0.01 3.3 ± 1.8 ns
(0.09)
–
Post-test 7.0 ± 5.0 – −2.1 ± 2.2 – –
180°·s−1 ﬂexor
peak torque, Nm
Mid-test 2.2 ± 1.4 – 3.0 ± 1.4 ns
(0.052)
–
Post-test 3.8 ± 1.8 0.048 −0.1 ± 1.8 – ns (0.08)
Grip strength, kg
Mid-test 2.1 ± 0.5 b0.01 2.1 ± 0.6 b0.01 –
Post-test 2.6 ± 0.6 b0.01 2.8 ± 0.7 b0.01 –
GUG, s
Mid-test −0.4 ± 0.2 0.04 −0.5 ± 0.2 .0.01 –
Post-test −0.6 ± 0.3 0.045 −0.7 ± 0.3 .0.03 –
* indicates signiﬁcant treatment group by gender interaction (treatment p-value indicated
below for gender).
a p values reported for signiﬁcant main effects unless there was a signiﬁcant treatment
by gender interaction, in which case results are indicated in footnote.
1 Males: 0.01.
2 Males: 0.02.
3 Males: 0.03.
4 Males: ns (0.09).
5 Males: 0.01.
6 Males: 0.005.
7 Males: ns (0.06).
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between groups (Table 4). Likewise, GUG time signiﬁcantly de-
creased from baseline to mid- and post-testing for both the REPLA
and REHMB groups, respectively, with no differences between groups
(Table 4).
3.2.3. Muscle quality
MQ60 increased with no differences between groups; mid-test
values were not signiﬁcant for REHMB (Table 5). MQ180 signiﬁcantly
increased at mid- and post-testing for the REPLA group, but did not
signiﬁcantly change from baseline to mid- or post-testing for the
REHMB group, with no differences between groups (Table 5). MQHG did
not signiﬁcantly change from baseline to mid- or post-testing for the
REPLA group, however, the REHMB group increased at mid- and post-
testing, with no differences between groups (Table 5).
3.3. Blood chemistries—Phases I and II
Analysis of blood chemistries revealed no clinically-signiﬁcant dif-
ferences within or between PLA and HMB treatments. The mean values
for total protein and SGOT were collectively higher for those who took
the placebo than HMB (p = 0.04 and p = 0.046, respectively); while
all values were within the expected and normal ranges. Uric acid was
higher for those who took the HMB treatment than the placebo
(p b 0.01), however, the mean uric acid values fell within the expected
and normal range. Absolute lymphocytes were higher for NEHMB than
NEPLA (p b 0.01), however, the percent lymphocytes were not different
among groups. There were no differences among groups for any other
blood markers.
3.4. Adverse events—Phases I and II
Overall, 25 adverse events (AEs; 24 mild; 1 moderate) and 2 seri-
ous AEs (SAEs) were reported during both Phases I and II. The AEs
were found to be “probably none” or “not” related to the study
protocol or product by the study physician. Four participants
discontinued the study due to AEs and/or SAEs. One withdrew from
the REHMB group after reporting a moderate AE due to pneumonia
and another withdrew from the REPLA group after reporting a frac-
ture due to fall. The two participants who reported SAEs exited
from the study between mid- and post-testing. One participant in
the NEHMB group was diagnosed with a urinary tract infection, was
hospitalized, and later died. Another man in the NEPLA group was di-
agnosed with throat cancer and withdrew from the study. NeitherAE/SAE was related to the study protocol or product as determined
by the study physician. No statistical differences or clinically-
relevant ﬁndings among the numbers of AEs were reported between
the HMB and PLA groups.
Table 5
Muscle quality changes after 12 weeks (Mid-test) and 24 weeks (post-test)
supplementation with placebo (PLA) or HMB in resistance-exercising (RE) study subjects.
REPLA REHMB Treatment
main
effecta
Mean ± SEM Within
group p
value
Mean ± SEM Within
group p
value
MQ60°·s−1 Nm/kg
Mid-test 0.6 ± 0.2 0.01 0.2 ± 0.1 ns
(0.09)
–
Post-test 1.1 ± 0.3 b0.01 0.5 ± 0.2 0.01 –
MQ 180°·s−1 Nm/kg
Mid-test 0.3 ± 0.1 0.03 0.2 ± 0.1 ns
(0.098)
–
Post-test 0.8 ± 0.2 0.01 0.3 ± 0.2 ns
(0.07)
–
MQ HG
Mid-test 0.2 ± 0.1 ns
(0.098)
0.3 ± 0.1 0.03 –
Post-test 0.2 ± 0.1 ns
(0.08)
0.4 ± 0.1 0.02 –
a p values reported for signiﬁcant main effects.
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Phase I of the current study demonstrated that prolonged supple-
mentation with CaHMB improved total lean mass (LM), strength, func-
tion and MQ without resistance exercise. In addition, the progressive,
high-intensity resistance training protocol used in Phase II resulted in
increased LM, strength, and MQ, with or without CaHMB. Moreover,
the CaHMB intervention in Phase II resulted in a signiﬁcant decreased
total fat mass along with the increased total lean mass and arm MQ
from the training. Therefore, these data suggest that strength, MQ,
body composition, and functionality in healthy older men and women
can be improved through CaHMB supplementation, with and without
resistance training.
Recent evidence suggests that CaHMB combined with arginine and
lysine (HMB-Arg-Lys) may partially blunt or reverse the age-related
changes in muscle mass (Baier et al., 2009; Flakoll et al., 2004). While
the current study only supplemented with CaHMB, the changes in
total lean body mass (0.40 kg NE, 0.39 kg RE) were similar to values
(0.20 kg & 0.56 kg) reported by Flakoll et al. (2004) and Baier et al.
(2009), respectively. Furthermore, our data show that CaHMB increased
leg leanmass 2.1% at both 12 and 24 weeks,whichwas similar to Flakoll
et al. (2004) who demonstrated an increase of 1.1% in thigh, arm and
forearm limb circumference.
It is currently thought that the effects of CaHMB in aging muscle are
mediated by altering protein balance. For example, Wilson et al. (2012)
demonstrated that CaHMB prevented the decline in muscle ﬁber dimen-
sions from young to old age using a rat model. These effects may have
been mediated by blunting the genes that regulate protein breakdown.
Moreover, Baier et al. (2009) suggested that CaHMB may improve
whole body protein metabolism in elderly individuals over the age of 65.
The initiation of resistance exercise in aging populations has resulted
in robust changes in lean body mass (Charette et al., 1991; Delecluse
et al., 2004; Fielding et al., 2002; Hunter et al., 2004; Schwartz and
Evans, 1995). We are aware of only one previous study that has exam-
ined the effects of CaHMB in conjunction with resistance exercise in
the elderly (Vukovich et al., 2001). Interestingly, the present results par-
tially disagreedwith Vukovich et al. (2001)who found that CaHMB com-
binedwith resistance training increased anthropometrically-determined
fat free mass more than resistance training alone. However, the de-
creases in fat mass observed in the CaHMB group (REHMB) in the present
study were consistent with the decreases in percent fat in the CaHMB
group reported by Vukovich et al. (2001). It should be noted that
Vukovich et al. (2001) used lower intensities (70% vs. 80% 1RM) and fre-
quencies (2 vs. 3 days) for resistance exercise than used in phase II of the
present study. Moreover, the resistance training program used in thecurrent study resulted in 26–41% attrition, which was higher than the
19–23% attrition observed during the 8-weeks of exercise used by
Vukovich et al. (2001). Breen and Phillips (2011) recently suggested
that low-intensity and high-repetition resistance exercise may be more
effective for older adults. Future studies should consider examining the
efﬁcacy of lower-intensity resistance training, with and without protein
and/or CaHMB supplementation, for improving exercise compliance in
the elderly.
Research suggests that after the age of 74, 30% of men and 66% of
women in the United States are incapable of lifting objects greater
than 4.5 kg (Jette and Branch, 1981). However, the neuromuscular sys-
tem is highly plastic and displays the capacity to respond to repeated
loading via an increase in strength in elderly populations (Charette
et al., 1991; Delecluse et al., 2004; Fielding et al., 2002; Hunter et al.,
2004; Moss et al., 1997; Schwartz and Evans, 1995). The current study
demonstrated that CaHMB alone (without training) elicited an increase
in strength, as well as GUG performance. Furthermore, both resistance
training alone, and when combined with CaHMB, increased upper and
lower body strength, with no differences between conditions.
Muscle quality has been suggested to be a better indicator of muscle
function than strength alone, especially when evaluating elderly adults
(Newman et al., 2003). While CaHMB had no effect on overall strength
compared to resistance training alone, it did increase MQ. Sarcopenia is
purposefully deﬁned to include the age-related loss of muscle mass and
function due to the observation that muscle mass alone may not ac-
count for the rapid deterioration of strength losses with age (Jette and
Branch, 1981). Therefore, it is possible that the reversal of this process
may also be predicated on increases in strength, without a concomitant
increase inmuscle size in older adults. This hypothesis is consistentwith
early work by Sale (1988) who demonstrated an extended time course
of neural versus hypertrophic adaptations to resistance exercise in the
elderly. It is likely that CaHMB is enhancing strength through increasing
the short-term energetic capacity of myoﬁbers (Pinheiro et al., 2012). It
was recently demonstrated that four weeks of CaHMB administration in
male Wistar rats increased intramuscular ATP and glycogen content by
up to 2- and 5-fold respectively (Pinheiro et al., 2012). It is therefore
possible that such metabolic changes enhance strength per unit area
of lean mass. However, further research is needed in human models to
examine the possible change in energetic capacity and its effect on
muscle quality.
One interesting ﬁnding regarding the CaHMB treatment in the
present study was its effect on fat mass, which was consistent with
Vukovich et al. (2001). CaHMB alone did not cause fat loss. However, re-
sistance training with or without CaHMB resulted in a signiﬁcant loss of
fatmass at week 12, whereas only the CaHMB groupwas able to further
the reduction in fat mass at week 24. Resistance exercise is not thought
to be a potent stimulus for total body fat loss (Binder et al., 2005; Ismail
et al., 2012). However, CaHMB is thought to improvemetabolic capacity
and fat utilization of myoﬁbers (Bruckbauer et al., 2012). In fact, recent
evidence suggested that CaHMB supplementation improved fatty acid
oxidation, adenosine monophosphate kinase (AMPK), and Sirt1 and
Sirt3 activity in adipocytes and in muscle cells (Bruckbauer et al.,
2012). Collectively, these proteins act to improvemitochondrial biogen-
esis, fat oxidation, and energy metabolism. Thus, it is conceivable that
the combination of elevated LM, coupledwith greaterMQ andmetabol-
ic capacity resulted in signiﬁcant fat loss at 24 weeks in the REHMB
group. Due to the elevated comorbidities associated with sarcopenic
obesity (Chung et al., 2012), future studies are needed to further inves-
tigate the potential combination of resistance exercise and CaHMB
supplementation for reducing fat mass.
5. Conclusion
In conclusion, the present data supports the consensus that
24 weeks of resistance training is an effective intervention for improv-
ing LM, strength, functional movement and MQ in elderly men and
1310 J.R. Stout et al. / Experimental Gerontology 48 (2013) 1303–1310women. However, there are three potential limitations: 1) low adher-
ence to high intensity resistance exercise programs, 2) discontinuation
of resistance exercise will result in rapid loss of beneﬁts, and 3) in frail
elderly, resistance exercise may not be adequate to reverse loss of
muscle function (Bamman et al., 2007; Moss et al., 1997). Accordingly,
non-exercise interventions (nutritional or pharmacological) that can
improve body composition, MQ and functionality, are critically
important. The ﬁndings of the present pilot study indicate that
CaHMB without RE enhances strength and MQ in elderly men and
women, thereby supporting its potential as a nutritional interven-
tion to prevent sarcopenia and its associated functional decline in
people as they age.
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